Orthopedic implant failure cases sit at the intersection of product liability and medical malpractice, and handling them as one without the other is a common intake mistake. A hip or knee implant that fails within three to five years of implantation, requires revision surgery, and causes documented complications including metallosis, osteolysis, or fracture may have failed because of a design or manufacturing defect, because of surgeon error in implantation, or both. Separating those theories early in the case determines which defendants stay in, which experts you need, and whether federal preemption is a barrier to recovery.
Product Defect Theories in Implant Cases
Three defect theories are available in orthopedic implant litigation: design defect, manufacturing defect, and failure to warn. Each requires different evidence and different experts.
Design defect claims argue that the implant's fundamental architecture creates an unreasonable risk of harm that a reasonable alternative design would have reduced. In hip implant litigation, the metal-on-metal bearing surface design that was widely used in the late 2000s and early 2010s is the prototypical design defect case: the articulating metal components generate cobalt-chromium particulate debris that migrates into surrounding tissue, causing metallosis and tissue necrosis at rates that exceeded comparable ceramic-on-polyethylene designs. Design defect analysis requires a biomechanical engineer and an orthopedic surgeon expert who can opine that the design created a foreseeable failure mechanism and that safer alternatives were available and feasible at the time of manufacture.
Manufacturing defect claims argue that the specific implant received by the plaintiff deviated from the manufacturer's own design specifications. These cases often involve a recalled lot: components with out-of-tolerance dimensions, surface finish defects that accelerate wear, or coating failures that compromise osseointegration. Preserving the explanted device after revision surgery is essential for manufacturing defect claims. The explanted implant is the primary physical evidence; chain of custody from the operating room to the laboratory determines whether it can be used. Coordinate with the revision surgeon before surgery to ensure the device is collected and preserved properly.
Failure to warn claims argue that the manufacturer knew of failure risks, adverse event rates, or patient population contraindications that were not adequately communicated to surgeons or patients. MAUDE (Manufacturer and User Facility Device Experience) database reports, which are public records at the FDA, document adverse event reports for specific device models. If the manufacturer received substantial adverse event reports of early failure before the plaintiff's implantation date and did not update its warnings or contraindication guidance, the failure-to-warn theory has a documentary foundation.
Federal Preemption and the Parallel Claim Strategy
The threshold question in any medical device product liability case is whether FDA preemption forecloses state tort claims. Under 21 U.S.C. Section 360k(a), which the Supreme Court addressed in Riegel v. Medtronic (2008), state common law claims that impose requirements different from or in addition to FDA requirements are preempted for Class III devices that cleared the PMA process. The PMA preemption applies only to Class III devices; Class II devices cleared through the 510(k) substantial equivalence pathway do not receive the same preemption protection.
Many orthopedic implants, including the majority of hip replacement systems currently on the market, cleared through the PMA process and carry full Riegel preemption protection for design defect claims. The path around preemption is the parallel claim: plaintiff argues that the manufacturer violated its own FDA-approved specifications (manufacturing defect) or violated FDA's good manufacturing practice requirements (GMP defect), both of which are parallel to federal requirements rather than adding to them. The parallel claim theory requires careful pleading and expert support but is the established route for preserving state tort claims against PMA Class III devices.
The 510(k) pathway operates differently. Devices that cleared through 510(k) do not carry PMA-level preemption, and the Supreme Court in Medtronic v. Lohr (1996) held that 510(k) clearance does not create the kind of specific federal requirement that triggers Section 360k(a) preemption. Many knee implant systems and some hip systems used 510(k) clearance, and those cases are not burdened by the full PMA preemption analysis.
Discovery From the Manufacturer
Manufacturer discovery in implant cases should be sent early and should be comprehensive. The categories of documents that matter most: internal design testing records and validation studies; adverse event reports and complaints received before the plaintiff's implantation date; MAUDE database submissions for the specific device model; design change history including any revisions to the original FDA-approved design; and internal communications about known failure mechanisms or elevated adverse event rates.
Many orthopedic device manufacturers have faced prior mass tort litigation for the same device families. If the manufacturer settled a prior MDL or produced documents in prior litigation, those document productions may be accessible through discovery in the current case or through the MDL docket. Check whether the device has a prior MDL history before building a new discovery plan from scratch; the prior litigation's document record is often the fastest route to the key internal engineering documents.
The Med-Mal Component
Even when the product defect theory is strong, do not close the med-mal inquiry. Surgeon selection and implantation technique affect implant longevity in documented ways. Cup positioning in total hip arthroplasty, in particular, has a significant effect on bearing surface wear and impingement rate. A cup placed outside the safe zone defined by the manufacturer's surgical technique guide contributes to accelerated wear and potential dislocation regardless of the implant design. If the post-implantation imaging shows cup malposition, the surgeon's technique is part of the failure analysis.
In cases with both a viable product defect claim and a viable malpractice claim, retaining both a biomechanical engineer and an orthopedic surgeon expert who can address both the device performance and the surgical technique is the standard approach. The expert who addresses product defect is typically an engineer; the expert who addresses surgical technique is a clinical surgeon. Do not ask one expert to address both opinions unless they are genuinely qualified in both domains.
For coverage of federal medical device preemption and the parallel claim doctrine in detail, see our product liability section. The medical malpractice standard-of-care framework for surgical device implantation is addressed in our medical malpractice coverage.
Practical Checklist for Implant Cases
- Determine whether the device cleared through PMA or 510(k) before committing to a design defect theory; PMA preemption shapes the pleading strategy.
- Preserve the explanted device at revision surgery; coordinate with the surgeon before the procedure.
- Pull MAUDE adverse event reports for the specific device model and compare pre-implantation reports to the manufacturer's warnings.
- Check whether the device has a prior MDL docket and whether prior document productions are accessible.
- Evaluate cup position and surgical technique in total hip cases; do not close the med-mal theory without reviewing the post-operative imaging.